Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.66 |
| ▸ | CTSL | P07711 | 6/20 | 0.61 |
| ▸ | CTSS | P25774 | 4/20 | 0.61 |
| ▸ | CTSB | P07858 | 2/20 | 0.61 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10904441 | 0.94 | CTSK (0.69) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL31720222 | 0.89 | SYK (0.58) | CTSKCTSLCTSSCTSBSYK | |
| SCHEMBL22144905 | 0.89 | SYK (0.58) | CTSKCTSLCTSSCTSBSYK | |
| SCHEMBL20529479 | 0.89 | SYK (0.58) | CTSKCTSLCTSSCTSBSYK | |
| SCHEMBL30407074 | 0.88 | CTSK (0.71) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL21885556 | 0.85 | CTSK (0.63) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL18154376 | 0.85 | CTSK (0.63) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL4862861 | 0.85 | CTSK (0.72) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL19944603 | 0.85 | CTSK (0.58) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL14493051 | 0.84 | CTSK (0.64) | CTSKCTSLCTSSCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313594-A1 | TWO-RESIDUE-EXTENDED PEPTIDE AND METHOD FOR PRODUCING SAME | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2025-10-09 | — | — | US | disclosed |
| EP-4527846-A1 | TWO-RESIDUE-EXTENDED PEPTIDE AND METHOD FOR PRODUCING SAME | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2025-03-26 | — | — | EP | disclosed |
| CN-119137136-A | Dual-residue extension peptide and preparation method thereof | 国立大学法人东海国立大学机构 | 2024-12-13 | — | — | CN | disclosed |
| WO-2023223714-A1 | TWO-RESIDUE-EXTENDED PEPTIDE AND METHOD FOR PRODUCING SAME | 国立大学法人東海国立大学機構 | 2023-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313594-A1 | TWO-RESIDUE-EXTENDED PEPTIDE AND METHOD FOR PRODUCING SAME | NPPA, NGLY1, ANPEP | CTSK 595/4885CTSL 190/4885CTSS 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.